Vaccine Platform

Mycobacterial – Inactivated

Phase of Development

Phase 2b

Candidate Overview

DAR-901 is an inactivated whole cell vaccine derived from a non-tuberculous mycobacterium and represents a scalable manufacturing process for SRL172.

Sponsor / Lead Developer: Dartmouth

Primary Indication: Prevention of TB disease

Target Population(s): Adolescents, Adults, and People living with HIV

Clinical Trials

Registry NumberNCT02712424
Clinical Trial PhasePhase 2b
Primary endpoint(s) for this clinical trialPrevention of Mtb infection or sustained infection
Target population(s) for clinical trialAdolescents
People without Mtb infection
Registry NumberNCT02063555
Clinical Trial PhasePhase 1
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults
People living with HIV
People without HIV